Synergistic Effect Research Of EGFR/HER2 Targeted Drugs

EGFR and HER2 belong to the tyrosine kinase receptor family.The mutation or overexpression of these receptors cause a dysregulation of kinase activity,which results in a sustained growth signal and carcinogenic transformation.Currently,cancers with EGFR or HER2 overexpression have been studied intensively,and approved a range of targeted kinase inhibitors and antibody drugs.However,studies have found that EGFR/HER2 overexpression is prevalent in many cancers,such as breast cancer,ovarian cancer and lung cancer.These receptor signals not only induce more efficient kinase activation,but also enhance the invasiveness of cancers and reduces the OS of patients.Therefore,the EGFR and HER2 are also considered to be two determinants of clinical response and prognosis.Although the treatment of EGFR or HER2 target drugs have achieved certain results,both primary and secondary resistance mechanisms limit the effectiveness of targeted therapies.The targets of kinase inhibitors and antibodies are very different,and there is a possibility of enhancing inhibition by a combination of non-overlapping targets.Therefore,the study of combination therapy for EGFR/HER2 overexpressing cancer has great significance.We established the overexpression system of EGFR or / and HER2 in 293 T cell and studied the effects of the targeted drugs on the kinase activity and the combination of kinase inhibitor and antibody.These basic study will deepen our understanding of the synergistic mechanisms of kinase inhibitor and antibody in the treatment of EGFR/HER2 overexpressing cancer and lay the foundation for the first-line treatment strategy of cancer with EGFR/HER2 overexpression.